Newsletter | May 14, 2022

05.14.22 -- Call It What You Like, This Biotech Model Makes Money
 
From The Editor
Call It What You Like, This Biotech Model Makes Money
 
By Louis Garguilo, Chief Editor, Outsourced Pharma

“We are a biotech that makes money,” replies Helen Torley, CEO, Halozyme, when I ask her what her company is exactly. A significant amount of money, along with notably high margins, and plenty of new drug opportunities. Here's the model for success.
Featured Editorial
5 Ways For Emerging Biotechs To Launch Smarter
By Eduardo Schur, EY
How To Overcome Potency Assay Development Challenges For Gene Therapies
By BioPhorum
Technical Due Diligence Considerations For Multisite Biopharma Acquisitions
By Anthony Grenier
Biopharma Patents: Satisfying Descriptions For Claimed Ranges
By Jonathan B. (J.B.) Fitzgerald, Ph.D., J.D., Glen K. Thurston, Ph.D., and Jeffrey D. Morton, Ph.D., J.D., Snell & Wilmer L.L.P.
Industry Insights
ADC Stands Out In The Crowd Of HER2-Targeted Conjugates
By Penelope Drake, Ph.D.
Is Your API Ready For Scale-Up? What To Demand From Your CDMO
By Justin A. Divan
How Can Contract Organizations Bridge The Talent Gap In Biopharma?
By Lisa McLaughlin
Embrace A 360-Degree Approach To Biopharmaceutical Testing Services
By Felipe Burns and Sherona Sirkisoon
Understanding Risks Of Biologic Drugs And Injectable Drug-Device Combination Products
By Fran L. DeGrazio
End-To-End Cell And Gene Therapy: From Development To Commercialization — Buy Or Build?
By Aldo Romano and Emily Moran
Lung Cancer Treatment By Inhaled Formulations
By Kimberly Shepard, Ph.D.
Considerations When Outsourcing Your Packaging Operations
By Yves Massicotte
Single-Vendor CDMOs Bring Speed And Cost Savings To The Table
Thermo Fisher Scientific
How To Use QbD Software To Improve An Existing Identification Method
Pfizer CentreOne
Transforming Your Biopharma Automation Capabilities
Cytiva
Create Brand Sustainability With Softgel Technology
Thermo Fisher Scientific
Balancing Cost Efficiencies In The Drug Development Process
Cambrex
How Shorter Needles With Thinner Walls Are Set To Improve The Injection Experience In Chronic Care
BD Medical - Pharmaceutical Systems
Biologic Drug Product Outsourcing Drivers By Company Size
ISR Reports
Best Practices On Health-Based Cleaning Limits In A Multiproduct Facility
PCI Pharma Services
Increasing mRNA Capabilities, Capacity
By Sebastian Almeida, Akron Biotech, Lloyd Jeffs, Precision Nanosystems, John Harmer, and Katarina Stenklo
Align CMC Strategy With Clinical Path Requirements And Timelines
By Lee Allen and Megan Mason
Developmental Testing Of IV Solutions
By Ryan Memmer
Applying Quality By Design To Pharmaceutical Research And Development
By Shawn Watson
Considerations For Migrating From Vial To Prefilled Syringe
By Martin Gonzalez, Ph.D.
Top Four Considerations For Tech Transfer Performance
By Lei Zheng
Analytical Considerations For Biopharmas During Commercialization
By Elena Gontarz, Ph.D., Michael Farris, Sharon Young, Ph.D., and Maria Johns, Ph.D.
Making Continuous Improvement Part Of The ‘Everyday’ In Pharmaceutical Clinical Services And Commercial Drug Packaging
Sharp
Pediatric Dosage Forms: Reformulation And Development Expertise
Cambrex
Accelerating The Development Of Orphan Drugs For Rare Diseases
Quotient Sciences
Adapting To Change: API Custom Development And Manufacturing
Cambrex
A Better Route For Commercial Manufacture: Improved Yields And Operability
Asymchem
Examining The Emergence Of Unit- And Bi-Dose Nasal Sprays
Catalent
The Composition And Value Of A Portfolio Analysis
Premier Consulting
Early Development To Clinic: De-Risking A Bioconjugate’s Journey
Lonza
A Toxicologist’s Viewpoint On Developing Oncology Drug Products
Thermo Fisher Scientific